{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:59:13Z","timestamp":1790834353979,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ecl.2019.08.005","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T17:06:32Z","timestamp":1568912792000},"page":"717-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Hypertension and Cardiovascular Mortality in Patients with Cushing Syndrome"],"prefix":"10.1016","volume":"48","author":[{"given":"Lynnette K.","family":"Nieman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2019.08.005_bib1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","article-title":"Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature","volume":"96","author":"Clayton","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib2","first-page":"2664","article-title":"Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure","volume":"84","author":"Colao","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2265.2011.04124.x","article-title":"Mortality and morbidity in Cushing's syndrome in New Zealand","volume":"75","author":"Bolland","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2019.08.005_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach","volume":"40","author":"Extabe","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2019.08.005_bib5","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2019.08.005_bib6","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","article-title":"High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO\/ISH guidelines","volume":"61","author":"Mancini","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2019.08.005_bib7","first-page":"3617","article-title":"11 beta-hydroxysteroiddehydrogense activity in Cushing\u2019s syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome","volume":"80","author":"Stewart","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib8","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2002-021558","article-title":"Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission","volume":"88","author":"Faggiano","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cen.12094","article-title":"Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment","volume":"78","author":"van der Paas","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2019.08.005_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ecl.2011.01.006","article-title":"Cushing's syndrome: all variants, detection, and treatment","volume":"40","author":"Sharma","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ecl.2019.08.005_bib11","first-page":"963","article-title":"Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome","volume":"74","author":"Ulick","year":"1992","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1161\/HYPERTENSIONAHA.109.134973","article-title":"Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome","volume":"54","author":"Bailey","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2019.08.005_bib13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","article-title":"Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486","volume":"61","author":"Nieman","year":"1985","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib14","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/01.HYP.33.5.1179","article-title":"11beta-hydroxysteroid dehydrogenase in cultured human vascular cells: possible role in the development of hypertension","volume":"33","author":"Hatakeyama","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2019.08.005_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/01.HYP.23.1.25","article-title":"Glucocorticoid increases angiotensin II type 1 receptor and its gene expression","volume":"23","author":"Sato","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2019.08.005_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1440-1797.2003.00215.x","article-title":"Glucocorticoids and the kidney","volume":"8","author":"Mangos","year":"2003","journal-title":"Nephrology"},{"key":"10.1016\/j.ecl.2019.08.005_bib17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/01.HYP.19.6.567","article-title":"Pressor responsiveness in corticosteroid-induced hypertension in humans","volume":"19","author":"Pirpiris","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2019.08.005_bib18","first-page":"855","article-title":"Studies on the pathogenesis of hypertension in Cushing\u2019s disease and acromegaly","volume":"280","author":"Ritchie","year":"1990","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.ecl.2019.08.005_bib19","first-page":"855","article-title":"Blood pressure responses to phenylephrine infusions in subjects with Cushing's syndrome","volume":"9","author":"McKnight","year":"1995","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.ecl.2019.08.005_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1530\/eje.0.1490549","article-title":"Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome","volume":"149","author":"Kirilov","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2019.08.005_bib21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2265.2007.02774.x","article-title":"Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing's disease from metabolic syndrome","volume":"66","author":"Setola","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2019.08.005_bib22","doi-asserted-by":"crossref","first-page":"13357","DOI":"10.1073\/pnas.96.23.13357","article-title":"Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension","volume":"96","author":"Wallerath","year":"1999","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.ecl.2019.08.005_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1210\/jcem-62-2-275","article-title":"Multiple factors contribute to the pathogenesis of hypertension in Cushing\u2019s syndrome","volume":"62","author":"Saruta","year":"1986","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib24","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0140-6736(83)91330-2","article-title":"Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease","volume":"23","author":"Axelrod","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2019.08.005_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/sleep\/15.6.514","article-title":"Sleep architecture and sleep apnea in patients with Cushing's disease","volume":"15","author":"Shipley","year":"1992","journal-title":"Sleep"},{"key":"10.1016\/j.ecl.2019.08.005_bib26","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.283.14.1829","article-title":"Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study","volume":"283","author":"Nieto","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2019.08.005_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-2006-944545","article-title":"Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors","volume":"38","author":"Albiger","year":"2006","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ecl.2019.08.005_bib28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/07853890.2016.1252055","article-title":"Markers of atherosclerosis in patients with Cushing's syndrome: a meta-analysis of literature studies","volume":"49","author":"Lupoli","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.ecl.2019.08.005_bib29","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/S0735-1097(03)00493-5","article-title":"Left ventricular structural and functional characteristics in Cushing\u2019s syndrome","volume":"41","author":"Muiesan","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2019.08.005_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2265.2011.04206.x","article-title":"Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure","volume":"76","author":"Toja","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2019.08.005_bib31","doi-asserted-by":"crossref","first-page":"E2144","DOI":"10.1210\/jc.2014-1783","article-title":"Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study","volume":"99","author":"Kamenick\u00fd","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib32","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1210\/jc.2012-3754","article-title":"Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography","volume":"98","author":"Neary","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib33","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF03347534","article-title":"Circadian blood pressure profile in patients with Cushing's syndrome before and after treatment","volume":"27","author":"Zacharieva","year":"2004","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.ecl.2019.08.005_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/07420528.2012.701127","article-title":"Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the \u201cnormotensive non-dipper\u201d paradox","volume":"30","author":"Hermida","year":"2013","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.ecl.2019.08.005_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11906-018-0897-4","article-title":"Chronotherapy for hypertension","volume":"20","author":"Bowles","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ecl.2019.08.005_bib36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2796.1993.tb01018.x","article-title":"Response of hypertension to conventional antihypertensive treatment and\/or steroidogenesis inhibitors in Cushing\u2019s syndrome","volume":"234","author":"Fallo","year":"1993","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.ecl.2019.08.005_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0002-9610(64)90251-X","article-title":"Surgical experience with the treatment of hypertension of Cushing's Syndrome","volume":"107","author":"Raker","year":"1964","journal-title":"Am J Surg"},{"key":"10.1016\/j.ecl.2019.08.005_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0895-7061(95)00299-5","article-title":"Effect of surgical treatment on hypertension in Cushing\u2019s syndrome","volume":"9","author":"Fallo","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ecl.2019.08.005_bib39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1210\/jcem-46-1-114","article-title":"Evidence for an angiotensinogenic mechanism of the hypertension of Cushing's syndrome","volume":"46","author":"Dalakos","year":"1978","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1054\/plef.2002.0388","article-title":"The effect of enalapril on PGI(2) and NO levels in hypertensive patients","volume":"66","author":"Girolamo","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.ecl.2019.08.005_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1291\/hypres.27.129","article-title":"Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress","volume":"27","author":"Yagi","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ecl.2019.08.005_bib42","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/DDDT.S199051","article-title":"Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects","volume":"13","author":"Sidharta","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ecl.2019.08.005_bib43","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1530\/EJE-13-0569","article-title":"Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up","volume":"169","author":"Ntali","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2019.08.005_bib44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000318566","article-title":"Cardiovascular disease in Cushing's syndrome: heart versus vasculature","volume":"92","author":"De Leo","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2019.08.005_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.beem.2017.03.002","article-title":"Growth hormone deficiency in treated acromegaly and active Cushing's syndrome","volume":"31","author":"Formenti","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib46","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.005_bib47","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's Syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852919300593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852919300593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:44:22Z","timestamp":1760175862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852919300593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0889852919300593"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2019.08.005","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension and Cardiovascular Mortality in Patients with Cushing Syndrome","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2019.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}